BCL2 and triple-negative breast carcinoma: These results are in agreement with the studies published on human breast cancer, where Bcl-2 positivity has been associated with favorable clinicopathologic features, such as smaller tumor size [9, 12, 50–56], and negative nodal status [12, 18, 51, 52], in both triple-negative and non-triple-negative breast cancer [57], although in the present study, Bcl-2 positivity of FMCs was not significantly correlated with the pathologic tumor size and nodal stage.